Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoyan Kang(Qilu Hospital of Shandong University), Meimei Si, Helong Zhang(Shanghai International Studies University), Weihua Yang(Shanxi Provincial Cancer Hospital), Zhehai Wang(Shandong Tumor Hospital), Sanyuan Sun, Xuezhi Hao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanqiu Zhao(Henan Cancer Hospital), Yanping Hu(Chinese People's Liberation Army), Jian Zhao(ShanghaiTech University), Huaize Geng(Qilu Hospital of Shandong University), Jianhua Chen(Xinjiang Medical University), Zhihong Zhang(Jiangsu Province Hospital), Yu Zhang(Beijing City University), Chunling Liu(Xinjiang Medical University), Jun Zhao(Beijing Institute of Technology), Hui Li(Shandong Tumor Hospital), Kangsheng Gu(Anhui Medical University), Yiping Zhang(Henan Normal University), Shucai Zhang(Northeastern University), Xiuwen Wang(Second Hospital of Shandong University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Runxiang Yang(Kunming Medical University), Lei Yang(First Affiliated Hospital of Xi'an Jiaotong University), Jinlu Shan(Army Medical University), Yan Yu(Binzhou Medical University), Chang-Lu Hu(Anhui Provincial Hospital), Yunpeng Liu(Shenyang Institute of Automation), Liangming Zhang(Yuhuangding Hospital), Xiaosheng Hang(Wuxi Fourth People's Hospital), Lin Wang(Shanxi Academy of Medical Sciences), Bangxian Tan(Affiliated Hospital of North Sichuan Medical College)
Cited by 24
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695